NGM Biopharmaceuticals, Inc.
NGMNASDAQHealthcare
$1.54
$-0.02(-1.28%)
Market Cap$128532096
P/E Ratio—
52W High$4.69
52W Low$0.6002
NGM Biopharmaceuticals, Inc. (NGM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NGM · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2024Report Date: May 2, 2024EPS Actual
-$0.58
Est. -$0.46 · -26.1%
Revenue
—
Fiscal Period
Q2 FY2024
FY ends December
Report Date
May 2, 2024
After Market Close
▼ Miss EPS
NGM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.52
Rev. $3.34B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.52
Rev. Est.$3.34B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q2 FY2024 | May 2, 2024 | -$0.46 | -$0.58 | -26.1% | — | — | — |
| ▲ Q1 FY2024 | Mar 11, 2024 | -$0.37 | -$0.33 | +10.8% | $0.00B | $0.00B | -70.5% |
| ▲ Q4 FY2023 | Nov 2, 2023 | -$0.40 | -$0.35 | +12.5% | $0.00B | $0.00B | -6.1% |
| — Q3 FY2023 | Aug 3, 2023 | -$0.46 | -$0.46 | +0.0% | $0.00B | $0.00B | -56.9% |
| ▼ Q2 FY2023 | May 4, 2023 | -$0.52 | -$0.58 | -11.5% | $0.00B | $0.01B | -63.4% |
| ▲ Q1 FY2023 | Feb 28, 2023 | -$0.52 | -$0.45 | +13.5% | $0.02B | $0.01B | +168.7% |
| ▲ Q4 FY2022 | Nov 3, 2022 | -$0.61 | -$0.59 | +3.3% | $0.01B | $0.01B | +12.0% |
| ▼ Q3 FY2022 | Aug 4, 2022 | -$0.55 | -$0.59 | -7.3% | $0.01B | $0.01B | -38.1% |
Q2 FY2024
May 2, 2024Miss
EPS Actual
-$0.58
EPS Est.
-$0.46
EPS Surpr.
-26.1%
Revenue
—
Q1 FY2024
Mar 11, 2024Beat
EPS Actual
-$0.33
EPS Est.
-$0.37
EPS Surpr.
+10.8%
Revenue
$0.00B
Q4 FY2023
Nov 2, 2023Beat
EPS Actual
-$0.35
EPS Est.
-$0.40
EPS Surpr.
+12.5%
Revenue
$0.00B
Q3 FY2023
Aug 3, 2023
EPS Actual
-$0.46
EPS Est.
-$0.46
EPS Surpr.
+0.0%
Revenue
$0.00B
Q2 FY2023
May 4, 2023Miss
EPS Actual
-$0.58
EPS Est.
-$0.52
EPS Surpr.
-11.5%
Revenue
$0.00B
Q1 FY2023
Feb 28, 2023Beat
EPS Actual
-$0.45
EPS Est.
-$0.52
EPS Surpr.
+13.5%
Revenue
$0.02B
Q4 FY2022
Nov 3, 2022Beat
EPS Actual
-$0.59
EPS Est.
-$0.61
EPS Surpr.
+3.3%
Revenue
$0.01B
Q3 FY2022
Aug 4, 2022Miss
EPS Actual
-$0.59
EPS Est.
-$0.55
EPS Surpr.
-7.3%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q3 FY2024 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Q2 FY2024 | $-0.34 | $-0.34 | $-0.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2023 | $-0.42 | $-0.42 | $-0.42 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 4 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2024 | May 2, 2024 | -26.1% | $1.54 | — | — |
| ▲ Q1 FY2024 | Mar 11, 2024 | +10.8% | $1.53 | $1.54 | +0.65% |
| ▲ Q4 FY2023 | Nov 2, 2023 | +12.5% | $0.78 | $0.80 | +3.12% |
| ▲ Q3 FY2023 | Aug 3, 2023 | +0.0% | $2.14 | $2.25 | +5.14% |
| ▼ Q2 FY2023 | May 4, 2023 | -11.5% | $3.90 | $3.94 | +1.03% |
| ▲ Q1 FY2023 | Feb 28, 2023 | +13.5% | $4.56 | $4.74 | +3.95% |
| ▲ Q4 FY2022 | Nov 3, 2022 | +3.3% | $5.10 | $4.99 | -2.16% |
| ▼ Q3 FY2022 | Aug 4, 2022 | -7.3% | $14.22 | $15.40 | +8.30% |
Q2 FY2024—
Report Date
May 2, 2024
EPS Beat/Miss
-26.1%
Price Before
$1.54
Price After
—
Q1 FY2024+0.65%
Report Date
Mar 11, 2024
EPS Beat/Miss
+10.8%
Price Before
$1.53
Price After
$1.54
Q4 FY2023+3.12%
Report Date
Nov 2, 2023
EPS Beat/Miss
+12.5%
Price Before
$0.78
Price After
$0.80
Q3 FY2023+5.14%
Report Date
Aug 3, 2023
EPS Beat/Miss
+0.0%
Price Before
$2.14
Price After
$2.25
Q2 FY2023+1.03%
Report Date
May 4, 2023
EPS Beat/Miss
-11.5%
Price Before
$3.90
Price After
$3.94
Q1 FY2023+3.95%
Report Date
Feb 28, 2023
EPS Beat/Miss
+13.5%
Price Before
$4.56
Price After
$4.74
Q4 FY2022-2.16%
Report Date
Nov 3, 2022
EPS Beat/Miss
+3.3%
Price Before
$5.10
Price After
$4.99
Q3 FY2022+8.30%
Report Date
Aug 4, 2022
EPS Beat/Miss
-7.3%
Price Before
$14.22
Price After
$15.40
Avg Beat Reaction+2.14%
Avg Miss Reaction+4.67%
Beat Rate5 / 8 quarters
Largest Move+8.30% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NGM ends December
NGM Biopharmaceuticals, Inc. (NGM) most recently reported earnings on May 2, 2024 for Q2 FY2024, posting EPS of $-0.58 — missing the analyst consensus of $-0.46 by -26.1%. The next NGM earnings date is expected around September 1, 2026.
Each quarter, investors track NGM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NGM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NGM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NGM earnings · 5 questionsNGM Biopharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. NGM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NGM historically reports after market close (AMC).
NGM earnings datewhen is NGM earningsNGM next earnings datewhen does NGM report earningsNGM earnings calendar
▸ Source: FMP · NGM Biopharmaceuticals, Inc. SEC filings · US GAAP · NGM Biopharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026